5402222026-10-305402222026-10-302026-10-30iso4217:INRxbrli:pure540222LAURUS LABS LIMITEDLAURUSLABSNOTLISTEDINE947Q01028NewAcquisition (including agreement to acquire)true2026-10-2914:47:002026-10-30Please note that the Turnover, PAT and Networth of the Target Company is mentioned in Canadian Dollar and the Cash Consideration / Cost of Acquisition is mentioned in USD in Crore in the 'Acquisition Sheet'. <BR> <BR> In order to avoid any confusion, please see below: <BR> <BR> Turnover of the target company: Canadian $ 1.65 million <BR> PAT of the target company: Canadian $ (0.23) million <BR> Networth of the target company: Canadian $ (0.26) million <BR> <BR> Consideration / Cost of acquisition: USD 3.75 million <BR> <BR> LAURUS LABS LIMITEDListed Entity (self)Galenvs Sciences Inc.1700000-200000300000falsefalsetruePrecision Contract Research and Development Organization (CRO/ CDMO)The proposed investment in Galenvs will bring synergy to the business of the Company and Galenvs to develop new markets for its products. While Galenvs will be engaged in Discovery, Lead Optimization and Pre-clinical process development from 1 µmol to 10 mmol, and will transfer the technology to the Company for Phase I/ II/ III of clinical trials and for commercialization for scale up. The Company will gain for R&D pipeline arm for oligonucleotides, depth on a line already exists, process IP and know-how and a North American business growth opportunity.NofalseThe Proposed Transaction is expected to be completed during the current financial year, subject to the completion of customary closing conditions and agreementsCash3800000The Proposed Transaction is contemplated by way of: a. primary subscription to 8,092,857 common shares of the Galenvs at a consideration of USD 2.75 million, equivalent to 44% of the post-issue paid-up equity capital of Galenvs on diluted basis; and b. secondary acquisition from Founder shareholder of 2,942,857 common shares of Galenvs at a consideration of USD 1.00 million, equivalent to 16% of the post-issue paid-up equity capital of Galenvs on diluted basis.38000000Galenvs is a Montréal (Canada) based precision contract research and development organization (CRO/ CDMO) specializing in custom oligonucleotide synthesis and functional magnetic-nanoparticle (MNP) technologies for the diagnostics and therapeutics markets. The Company operates a vertically integrated platform spanning discovery, optimization, synthesis, purification, validation and pilot-scale production. Galenvs operates R&D and laboratory facilities in Montréal supporting oligonucleotide synthesis, purification, analytical testing, magnetic nanoparticle development and related process development activities.2016-09-26Galenvs has business operations in Montréal, Canada and it has presence in North America.